Shopping Cart
Remove All
Your shopping cart is currently empty
LysRs-IN-2 is a lysine tRNA synthetase (KRS) inhibitor with antiparasitic activity that inhibits Plasmodium falciparum KRS (PfKRS) and Cryptosporidium minum KRS (CpKRS), and is used in the study of malaria infections.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $112 | In Stock | In Stock | |
| 5 mg | $328 | In Stock | In Stock | |
| 10 mg | $519 | In Stock | In Stock | |
| 25 mg | $833 | In Stock | In Stock | |
| 50 mg | $1,130 | In Stock | In Stock | |
| 100 mg | $1,530 | In Stock | In Stock | |
| 200 mg | $1,980 | - | In Stock |
| Description | LysRs-IN-2 is a lysine tRNA synthetase (KRS) inhibitor with antiparasitic activity that inhibits Plasmodium falciparum KRS (PfKRS) and Cryptosporidium minum KRS (CpKRS), and is used in the study of malaria infections. |
| Targets&IC50 | CpKRS:0.13 μM, Cryptosporidium minis:2.5 μM (EC50), PfKRS:0.015 μM, P. falciparum strain 3D7:0.27 μM (EC50), HepG2 cells:49 μM (EC50), lysyl-tRNA synthetase (HsKRS) (human):1.8 μM |
| In vitro | LysRs-IN-2 is a lysyl-tRNA synthetase (KRS) inhibitor with half inhibitory concentrations (IC50) of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNA synthetase (PfKRS) and Cryptosporidium lysyl-tRNA synthetase (CpKRS) respectively.[1] LysRs-IN-2 showed significant activity against P. falciparum strain 3D7 (EC50=0.27 μM), human lysyl-tRNA synthetase (HsKRS) (IC50=1.8 μM), HepG2 cells (EC50=49 μM), and Cryptosporidium minis (EC50=2.5 μM) in a whole-cell assay. [1] |
| In vivo | In the P. falciparum SCID mouse model, LysRs-IN-2 (1.5 mg/kg; orally once daily for 4 days) reduced parasitemia levels by 90%. In NOD SCID gamma mice and INF-γ knockout mice (Cryptosporidium minis model), LysRs-IN-2 (20 mg/kg; orally once daily for 7 days) significantly reduced parasite excretion. [1] |
| Molecular Weight | 355.31 |
| Formula | C17H16F3NO4 |
| Cas No. | 2170696-76-9 |
| Smiles | O=C1C=C(OC2=CC=C(F)C=C12)C(=O)NCC3(O)CCC(F)(F)CC3 |
| Relative Density. | 1.44 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (140.72 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.63 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.